Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | December 26, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date December 26, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,053 |
Reported balance
After 2025-12-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-26 · Sale · Disposed 7,530 · Balance 69,053 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2025 Filed Dec 30, 2025 22:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 7,530 | $70.00 | $527,100.00 |
DisclosureSEC source: 0001506045-25-000007 · wk-form4_1767134785.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,053 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:40 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001506045-25-000005 · wk-form4_1766101217.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,583 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,750 | $56.39 | $493,412.50 |
DisclosureSEC source: 0001506045-25-000003 · wk-form4_1764630617.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,764 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 23:04 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 16,733 | $22.99 | $384,691.67 |
DisclosureSEC source: 0001628280-24-052270 · wk-form4_1734735889.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,514 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,000 | $38.63 | $38,630.00 |
DisclosureSEC source: 0001628280-24-001423 · wk-form4_1705446376.xml · nonDerivative · entry 2 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,778 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $38.32 to $39.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,147 | $37.80 | $81,156.60 |
DisclosureSEC source: 0001628280-24-001423 · wk-form4_1705446376.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,778 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $37.51 to $38.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:03 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 14,987 | $25.41 | $380,819.67 |
DisclosureSEC source: 0001628280-23-041974 · wk-form4_1703019770.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,825 F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 20:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003108 · doc4.xml · derivative · entry 2 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 20:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003108 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,838 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002588 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,971 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 01:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,400 | $66.82 | $227,188.00 |
DisclosureSEC source: 0001209191-21-071561 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,571 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to an upcoming vesting of restricted stock units in January 2022. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:24 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001562 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,971 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,000 | $48.00 | $480,000.00 |
DisclosureSEC source: 0001209191-20-054714 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:48 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 26,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010599 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,971 F1 · shares: When the Board determined its 2019 compensation, Dr. Ferrari's equity compensation was limited by the policies of his employer. During 2019, Dr. Ferrari became no longer subject to these limitations. This award makes up the difference between the number of shares Dr. Ferrari was originally awarded in January 2019 and the number of shares awarded to other directors of the Company's Board in January 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001338 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,400 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 23:19 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 17,756 | $27.61 | $490,243.16 |
DisclosureSEC source: 0001209191-19-039549 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.58 to $27.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 3,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001548 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,656 Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 00:40 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 3,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063581 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,227 F1 · balance_after: This balance reflects the cancellation of 50,000 restricted stock units that were previously granted and reported on January 1, 2017. Dr. Ferrari's employer limits the amount of compensation he can take, and as such, these restricted stock units were subsequently cancelled. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001627 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,768 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.